Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors
- PMID: 11248033
- PMCID: PMC30608
- DOI: 10.1073/pnas.061562898
Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors
Abstract
Cytochrome P450 14alpha-sterol demethylases (CYP51) are essential enzymes in sterol biosynthesis in eukaryotes. CYP51 removes the 14alpha-methyl group from sterol precursors such as lanosterol, obtusifoliol, dihydrolanosterol, and 24(28)-methylene-24,25-dihydrolanosterol. Inhibitors of CYP51 include triazole antifungal agents fluconazole and itraconazole, drugs used in treatment of topical and systemic mycoses. The 2.1- and 2.2-A crystal structures reported here for 4-phenylimidazole- and fluconazole-bound CYP51 from Mycobacterium tuberculosis (MTCYP51) are the first structures of an authentic P450 drug target. MTCYP51 exhibits the P450 fold with the exception of two striking differences-a bent I helix and an open conformation of BC loop-that define an active site-access channel running along the heme plane perpendicular to the direction observed for the substrate entry in P450BM3. Although a channel analogous to that in P450BM3 is evident also in MTCYP51, it is not open at the surface. The presence of two different channels, with one being open to the surface, suggests the possibility of conformationally regulated substrate-in/product-out openings in CYP51. Mapping mutations identified in Candida albicans azole-resistant isolates indicates that azole resistance in fungi develops in protein regions involved in orchestrating passage of CYP51 through different conformational stages along the catalytic cycle rather than in residues directly contacting fluconazole. These new structures provide a basis for rational design of new, more efficacious antifungal agents as well as insight into the molecular mechanism of P450 catalysis.
Figures
Similar articles
-
A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.J Med Chem. 2000 Jun 29;43(13):2493-505. doi: 10.1021/jm990589g. J Med Chem. 2000. PMID: 10891108
-
Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51.J Inorg Biochem. 2001 Dec 15;87(4):227-35. doi: 10.1016/s0162-0134(01)00388-9. J Inorg Biochem. 2001. PMID: 11744060
-
Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02242-17. doi: 10.1128/AAC.02242-17. Print 2018 Mar. Antimicrob Agents Chemother. 2018. PMID: 29263059 Free PMC article.
-
An old activity in the cytochrome P450 superfamily (CYP51) and a new story of drugs and resistance.Biochem Soc Trans. 2001 May;29(Pt 2):122-8. doi: 10.1042/0300-5127:0290122. Biochem Soc Trans. 2001. PMID: 11356139 Review.
-
Recent advances in antifungal drug development targeting lanosterol 14α-demethylase (CYP51): A comprehensive review with structural and molecular insights.Chem Biol Drug Des. 2023 Sep;102(3):606-639. doi: 10.1111/cbdd.14266. Epub 2023 May 23. Chem Biol Drug Des. 2023. PMID: 37220949 Review.
Cited by
-
Phytochemical Composition and Pharmacological Activities of Three Essential Oils Collected from Eastern Morocco (Origanum compactum, Salvia officinalis, and Syzygium aromaticum): A Comparative Study.Plants (Basel). 2023 Sep 25;12(19):3376. doi: 10.3390/plants12193376. Plants (Basel). 2023. PMID: 37836118 Free PMC article.
-
Synthesis, Antifungal Activities, Molecular Docking and Molecular Dynamic Studies of Novel Quinoxaline-Triazole Compounds.ACS Omega. 2023 Jun 26;8(27):24573-24585. doi: 10.1021/acsomega.3c02797. eCollection 2023 Jul 11. ACS Omega. 2023. PMID: 37457491 Free PMC article.
-
The Specific Binding and Promotion Effect of Azoles on Human Aldo-Keto Reductase 7A2.Metabolites. 2023 Apr 27;13(5):601. doi: 10.3390/metabo13050601. Metabolites. 2023. PMID: 37233642 Free PMC article.
-
Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.Drug Metab Dispos. 2023 Jun;51(6):685-699. doi: 10.1124/dmd.122.001008. Epub 2023 Mar 22. Drug Metab Dispos. 2023. PMID: 36948592 Free PMC article. Review.
-
Structure Based Discovery of Inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosis.Chemistry. 2023 May 22;29(29):e202203868. doi: 10.1002/chem.202203868. Epub 2023 Apr 12. Chemistry. 2023. PMID: 36912255
References
-
- Trzaskos J, Fischer R, Favata M. J Biol Chem. 1986;261:16937–16942. - PubMed
-
- Aoyama Y, Yoshida Y, Sonoda Y, Sato Y. J Biol Chem. 1989;264:18502–18505. - PubMed
-
- Frye L L, Leonard D A. Crit Rev Biochem Mol Biol. 1999;34:123–140. - PubMed
-
- Koltin Y, Hitchcock C A. Curr Opin Chem Biol. 1997;1:176–182. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
